Oct 2 (Reuters) - Metabasis Therapeutics (MBRX.O) said European regulators have granted orphan drug status to its experimental drug to treat hepatocellular carcinoma, or primary liver cancer, in the European Union.
Orphan drug status is given to drugs that have the potential to treat rare diseases. Once approved, the product may qualify for 10 years of marketing exclusivity in the EU. (Reporting by Jennifer Robin Raj in Bangalore)
OSLO (Reuters) - There will be no "precipitous drawdown" of U.S. forces in Afghanistan and U.S. troops could still be in the country for years to come, President Barack Obama said on Thursday.
Recovering from a punishing global recession has forced the world's richest nations to pay dearly, prompting subdued growth prospects and delayed sighs of relief. Full Article
Did the worst downturn in 70 years leave a permanent scar? Top money managers like Tom Metzold examine how a "new normal" will shape things to come. Full Article
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
